169 related articles for article (PubMed ID: 27080149)
1. Modern approaches to the ocular delivery of cyclosporine A.
Agarwal P; Rupenthal ID
Drug Discov Today; 2016 Jun; 21(6):977-88. PubMed ID: 27080149
[TBL] [Abstract][Full Text] [Related]
2. Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.
Yu Y; Chen D; Li Y; Yang W; Tu J; Shen Y
Drug Deliv; 2018 Nov; 25(1):888-899. PubMed ID: 29631468
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems.
Rawat G; Kolhe S; Rana D; Salave S; Benival D
Crit Rev Ther Drug Carrier Syst; 2023; 40(5):1-45. PubMed ID: 37522548
[TBL] [Abstract][Full Text] [Related]
4. Reformulating cyclosporine A (CsA): More than just a life cycle management strategy.
Guada M; Beloqui A; Kumar MN; Préat V; Dios-Viéitez Mdel C; Blanco-Prieto MJ
J Control Release; 2016 Mar; 225():269-82. PubMed ID: 26829101
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts.
Lallemand F; Schmitt M; Bourges JL; Gurny R; Benita S; Garrigue JS
Eur J Pharm Biopharm; 2017 Aug; 117():14-28. PubMed ID: 28315447
[TBL] [Abstract][Full Text] [Related]
6. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs.
Agarwal P; Scherer D; Günther B; Rupenthal ID
Int J Pharm; 2018 Mar; 538(1-2):119-129. PubMed ID: 29339249
[TBL] [Abstract][Full Text] [Related]
7. Self-assembling colloidal system for the ocular administration of cyclosporine A.
Luschmann C; Tessmar J; Schoeberl S; Strauß O; Luschmann K; Goepferich A
Cornea; 2014 Jan; 33(1):77-81. PubMed ID: 24162754
[TBL] [Abstract][Full Text] [Related]
8. Silk Fibroin Formed Bioadhesive Ophthalmic Gel for Dry Eye Syndrome Treatment.
Hao T; Tang L; Xu Q; Wang W; Li Z; Shen Y; Xu B; Luo H; Li Q; Wang J; Zhang J
AAPS PharmSciTech; 2024 Apr; 25(5):92. PubMed ID: 38684590
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in cyclosporine drug delivery: challenges and opportunities.
Patel D; Wairkar S
Drug Deliv Transl Res; 2019 Dec; 9(6):1067-1081. PubMed ID: 31144214
[TBL] [Abstract][Full Text] [Related]
10. Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production.
Liu Y; Wang Y; Yang J; Zhang H; Gan L
Int J Pharm; 2019 Jun; 565():133-142. PubMed ID: 31075435
[TBL] [Abstract][Full Text] [Related]
11. Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers.
Di Tommaso C; Torriglia A; Furrer P; Behar-Cohen F; Gurny R; Möller M
Int J Pharm; 2011 Sep; 416(2):515-24. PubMed ID: 21219997
[TBL] [Abstract][Full Text] [Related]
12. Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits.
Weiss SL; Kramer WG
J Ocul Pharmacol Ther; 2019 Sep; 35(7):395-402. PubMed ID: 31355703
[No Abstract] [Full Text] [Related]
13. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Aksungur P; Demirbilek M; Denkbaş EB; Vandervoort J; Ludwig A; Unlü N
J Control Release; 2011 May; 151(3):286-94. PubMed ID: 21241752
[TBL] [Abstract][Full Text] [Related]
15. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
Leonardi A; Flamion B; Baudouin C
Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
[TBL] [Abstract][Full Text] [Related]
16. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
Dutescu RM; Panfil C; Merkel OM; Schrage N
Eur J Pharm Biopharm; 2014 Sep; 88(1):123-8. PubMed ID: 24844949
[TBL] [Abstract][Full Text] [Related]
17. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
[TBL] [Abstract][Full Text] [Related]
18. Clinical review: topical ophthalmic use of cyclosporin A.
Utine CA; Stern M; Akpek EK
Ocul Immunol Inflamm; 2010 Oct; 18(5):352-61. PubMed ID: 20735287
[TBL] [Abstract][Full Text] [Related]
19. Formulation and evaluation of Cyclosporin A emulgel for ocular delivery.
Shen Y; Ling X; Jiang W; Du S; Lu Y; Tu J
Drug Deliv; 2015; 22(7):911-7. PubMed ID: 24401095
[TBL] [Abstract][Full Text] [Related]
20. Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease.
Mandal A; Gote V; Pal D; Ogundele A; Mitra AK
Pharm Res; 2019 Jan; 36(2):36. PubMed ID: 30617777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
